Sk Bioscience Co., Ltd.

Teawoo Kwon

Eun-som Kim

Ki-weon Seo

Hun Rae Kim

Dong Soo Ham

Seung-hye Hong

Chi-Yong Kim

YoonJae Lee

Su Jeen Lee

The present invention provides a respiratory syncytial virus (RSV) recombinant fusion protein (F protein) in which a polymerization domain derived from a foreign protein is bound to the C terminal of a fusion protein (F protein) lacking a transmembrane domain of a wild-type respiratory syncytial virus (RSV) fusion protein (F protein). The recombinant fusion protein of the present invention is soluble and can retain an F protein trimer. Excellent immune-inducing effects can be expected from the recombinant fusion protein of the present invention, and vaccine composition containing same.

Respiratory syncytial virus recombinant F protein and vaccine composition containing same

The present invention provides a recombinant attenuated respiratory syncytial virus (RSV) comprising F protein of stabilized pre-fusion RSV, or comprising protein consisting of the amino acid sequence represented by SEQ ID NO: 2 or functional fragment thereof, and provides genome of the recombinant RSV and a recombinant vector comprising the genome. The recombinant attenuated RSV can be provided as a live vaccine strain which maintains infectability and has excellent safety and stability.

Recombinant RSV live vaccine strain and the preparing method thereof

The present invention provides a recombinant antigen protein for preventing SARS-coronavirus-2 infection, comprising a polypeptide derived from an S1 subunit of a spike protein of SARS-coronavirus-2 and a polypeptide constituting a tetanus toxin (TT) epitope P2 domain, and a vaccine composition comprising the same.

Vaccine composition for prevention or treatment of SARS-coronavirus-2 infection

Growing community of inventors

Seongnam-si, South Korea

Teawoo Kwon